Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M288,980Revenue $M70,074Net Margin (%)22.0Altman Z-Score5.0
Enterprise Value $M271,424EPS $5.2Operating Margin %26.1Piotroski F-Score4
P/E(ttm)19.2Beneish M-Score-2.8Pre-tax Margin (%)27.4Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %4.3Quick Ratio2.2Cash flow > EarningsY
Price/Sales5.45-y EBITDA Growth Rate %3.5Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow18.9y-y EBITDA Growth Rate %-18.2ROA % (ttm)14.1Higher Current Ratio y-yN
Dividend Yield %2.9PEG5.5ROE % (ttm)25.9Less Shares Outstanding y-yY
Payout Ratio %56.0Shares Outstanding M2,767ROIC % (ttm)31.4Gross Margin Increase y-yN

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJYacktman Focused Fund 2015-12-31 Reduce-0.17%$93.42 - $105.25
($100.68)
$ 100.54-0%Reduce -3.85%2,500,000
JNJDonald Yacktman 2015-12-31 Reduce-0.15%$93.42 - $105.25
($100.75)
$ 100.54-0%Reduce -3.23%7,316,129
JNJKen Fisher 2015-12-31 Add0.03%$93.42 - $105.25
($100.68)
$ 100.54-0%Add 1.18%10,815,964
JNJMario Gabelli 2015-12-31 Add0.01%$93.42 - $105.25
($100.75)
$ 100.54-0%Add 4.54%332,287
JNJJames Barrow 2015-12-31 Reduce-0.01%$93.42 - $105.25
($100.75)
$ 100.54-0%Reduce -0.38%15,342,046
JNJRichard Pzena 2015-12-31 Add$93.42 - $105.25
($100.75)
$ 100.54-0%Add 0.03%1,174,524
JNJYacktman Focused Fund 2015-09-30 Add0.17%$90.73 - $101.11
($96.79)
$ 100.544%Add 4.00%2,600,000
JNJTweedy Browne 2015-09-30 Reduce-0.17%$90.73 - $101.11
($96.79)
$ 100.544%Reduce -1.60%3,855,936
JNJCharles Brandes 2015-09-30 Buy 0.16%$90.73 - $101.11
($96.79)
$ 100.544%New holding118,509
JNJJohn Rogers 2015-09-30 Add0.12%$90.73 - $101.11
($96.79)
$ 100.544%Add 13.06%884,154
JNJYacktman Fund 2015-09-30 Add0.12%$90.73 - $101.11
($96.79)
$ 100.544%Add 2.86%3,600,000
JNJDonald Yacktman 2015-09-30 Add0.07%$90.73 - $101.11
($96.79)
$ 100.544%Add 1.59%7,560,334
JNJDavid Dreman 2015-09-30 Sold Out -0.05%$90.73 - $101.11
($96.79)
$ 100.544%Sold Out0
JNJJames Barrow 2015-09-30 Reduce-0.03%$90.73 - $101.11
($96.79)
$ 100.544%Reduce -1.49%15,399,839
JNJTom Gayner 2015-09-30 Add0.02%$90.73 - $101.11
($96.79)
$ 100.544%Add 1.39%582,200
JNJT Rowe Price Equity Income Fund 2015-09-30 Add0.02%$90.73 - $101.11
($96.79)
$ 100.544%Add 0.86%4,672,800
JNJKen Fisher 2015-09-30 Add0.01%$90.73 - $101.11
($96.79)
$ 100.544%Add 0.45%10,689,483
JNJFirst Eagle Investment 2015-09-30 Reduce-0.01%$90.73 - $101.11
($96.79)
$ 100.544%Reduce -1.50%1,585,928
JNJMario Gabelli 2015-09-30 Add$90.73 - $101.11
($96.79)
$ 100.544%Add 0.86%317,847
JNJDodge & Cox 2015-09-30 Reduce$90.73 - $101.11
($96.79)
$ 100.544%Reduce -3.40%36,935
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fasolo PeterVP, Global Human Resources 2016-02-03Sell151,385$104.12-3.44view
Ullmann Michael HVP, General Counsel 2015-11-20Sell17,650$102.47-1.88view
Caruso Dominic JVP, Finance; CFO 2015-11-02Sell20,569$102.21-1.63view
Kapusta Ronald AController, CAO 2015-10-23Sell6,239$99.680.86view
PRINCE CHARLESDirector 2015-08-06Buy2,500$99.251.3view
PRINCE CHARLESDirector 2015-06-02Buy2,500$99.221.33view
Stoffels PaulusChief Scientific Officer 2015-04-28Sell187,250$100.73-0.19view
Fasolo PeterVP, Global Human Resources 2015-03-05Sell115,307$102.4-1.82view
COSGROVE STEPHEN JCorporate Controller 2014-11-05Sell2,490$108.55-7.38view
Ullmann Michael HVP, General Counsel 2014-10-31Sell17,350$107.43-6.41view

Press Releases about JNJ :

Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Consider This Market with Negligible Volatility and Consistently Rising Values Feb 05 2016 
    Valeant's Share Price Continues to Decline Feb 05 2016 
    Johnson & Johnson: Dividend Aristocrats Part 50 Jan 27 2016 
    Three Stock Picks for 2016 Jan 15 2016 
    Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
    Why Dividend Growth Investing Should Be Your New Year’s Resolution Jan 03 2016 
    Dividend Aristocrats Part 39: Kimberly-Clark Dec 30 2015 
    5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
    Analyzing Amgen's Dividend Hike Dec 20 2015 
    Mairs and Power Buys American Express, Pfizer in 3rd Quarter Dec 10 2015 

    More From Other Websites
    [$$] J&J, AbbVie Shares Drop on Potential Drug Competition Feb 05 2016
    Call Martin Shkreli Whatever You Want, But Not A Pharma CEO Feb 05 2016
    The 4 Stocks That Tanked the Dow on Friday Feb 05 2016
    [$$] J&J, AbbVie Shares Drop on Potential Drug Competition Feb 05 2016
    Techs Tumble in Early Trade; Tyson Foods Wings Higher Feb 05 2016
    String of Q4 Earnings Beat Fails to Revive Pharma ETFs Feb 05 2016
    Celltrion’s Copy of J&J’s Remicade Gets FDA Staff Support Feb 05 2016
    Cheap Exposure to Large-Value Stocks Feb 05 2016
    [$$] Activist investors: hard drugs Feb 04 2016
    Stock Market Today - January U.S. Jobless Claims Up, Stock Futures Down Feb 04 2016
    Seeking Value, Growth and Momentum -- Analyst Notes on Comcast, Coca-Cola, Johnson & Johnson and 3M Feb 04 2016
    A Cure for Diabetes Is Moving Closer Toward Reality Feb 04 2016
    US company tests possible diabetes cure Feb 04 2016
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK